## TAKEDA PHARMACEUTICAL CORP LTD.

ISIN: JP3463000004 WKN: 4502 Asset Class: Stock



#### **Company Profile**

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

### Financial figures, Fiscal year: from 01.04. to 31.03.

|                                |                    | _                      |                    |                        |                    |                        |
|--------------------------------|--------------------|------------------------|--------------------|------------------------|--------------------|------------------------|
|                                | 2024               |                        | 2023               |                        | 2022               |                        |
| Financial figures              | Assets             | Liabilities and equity | Assets             | Liabilities and equity | Assets             | Liabilities and equity |
| Current assets                 | 2,558,580,000,000  |                        | 2,397,956,000,000  |                        | 2,593,642,000,000  |                        |
| Common stock capital           |                    | 1,676,596,000,000      |                    | 1,676,345,000,000      |                    | 1,676,263,000,000      |
| Fixed assets                   | 12,550,212,000,000 |                        | 11,559,794,000,000 |                        | 10,584,376,000,000 |                        |
| Equity capital of a company    |                    | 7,274,005,000,000      |                    | 6,354,671,000,000      |                    | 5,683,523,000,000      |
| Cash and cash equivalents      | 457,800,000,000    |                        | 229,557,000,000    |                        | 849,695,000,000    |                        |
| Accrued liabilities            |                    | 158,255,000,000        |                    | 183,563,000,000        |                    | 198,046,000,000        |
| Other assets                   | -                  |                        | -                  |                        | -                  |                        |
| Current liabilities            |                    | 2,313,103,000,000      |                    | 2,481,940,000,000      |                    | 2,145,730,000,000      |
| Prepayments and accrued income | -                  |                        | -                  |                        | -                  |                        |
| Non-current liabilities        |                    | 5,521,685,000,000      |                    | 5,121,140,000,000      |                    | 5,348,766,000,000      |
| Different income               |                    | -                      |                    | -                      |                    | -                      |
| Other liabilities              |                    | 773,152,000,000        |                    | 204,488,000,000        |                    | 146,430,000,000        |
| Total assets                   | 15,108,792,000,000 | 15,108,792,000,000     | 13,957,750,000,000 | 13,957,750,000,000     | 13,178,018,000,000 | 13,178,018,000,000     |

#### **Balance notes**

|                     | 2024    | 2023    | 2022    |
|---------------------|---------|---------|---------|
| Accounting standard | IFRS    | IFRS    | IFRS    |
| Employees           | -       | 49,095  | 47,347  |
| Equity ratio        | 48.15%  | 45.53%  | 43.13%  |
| Debt-equity ratio   | 107.69% | 119.63% | 131.84% |

## Others

|                  | 2024     | 2023   | 2022   |
|------------------|----------|--------|--------|
| Tax Expense Rate | -197.34% | 15.13% | 22.77% |

# TAKEDA PHARMACEUTICAL CORP LTD.

ISIN: JP3463000004 WKN: 4502 Asset Class: Stock

### Income statement

|  | 2024              | 2023              | 2022              |
|--|-------------------|-------------------|-------------------|
| Turnover   | 4,263,762,000,000 | 4,027,478,000,000 | 3,569,006,000,000 |
| Net income   | 144,067,000,000   | 317,017,000,000   | 230,059,000,000   |
| EBIT   | 1,263,042,500     | 3,036,175,400     | 2,684,960,200     |
| Operating income before taxes                                | 46,318,000,000    | 383,720,000,000   | 317,938,000,000   |
| Cash Flow  | 640,321,000,000   | 877,217,000,000   | 1,021,218,000,000 |
| Net interest income  | -167,757,000,000  | -130,886,000,000  | -137,140,000,000  |
| Research and development expenses                            | 729,924,000,000   | 633,325,000,000   | 526,087,000,000   |
| Income taxes   | -91,406,000,000   | 58,052,000,000    | 72,405,000,000    |
| Result from investments in subsidaries, associates and other | 6,473,000,000     | -8,630,000,000    | -15,367,000,000   |
| Revenues per employee  | -                 | 484,003           | 444,741           |

#### **Board of Directors**

| Masami lijima        | Chairman of Supervisory Board |
|----------------------|-------------------------------|
| Andrew Plump         | Member of Supervisory Board   |
| John Maraganore      | Member of Supervisory Board   |
| Steven Gillis        | Member of Supervisory Board   |
| Constantine Saroukos | Member of Supervisory Board   |
| Emiko Higashi        | Member of Supervisory Board   |
| lan Clark            | Member of Supervisory Board   |
| Jean-Luc Butel       | Member of Supervisory Board   |
| Kimberly Reed        | Member of Supervisory Board   |
| Koji Hatsukawa       | Member of Supervisory Board   |
| Michel Orsinger      | Member of Supervisory Board   |
| Miki Tsusaka         | Member of Supervisory Board   |
| Yoshiaki Fujimori    | Member of Supervisory Board   |

## Members of Management Board

| Christophe Weber   | Chairman of Managing Board    |
|--------------------|-------------------------------|
| Andrew Plump       | Member of Executive Committee |
| Costa Saroukos     | Member of Executive Committee |
| Gabriele Ricci     | Member of Executive Committee |
| Giles Platford     | Member of Executive Committee |
| Julie Kim          | Member of Executive Committee |
| Koki Sato          | Member of Executive Committee |
| Lauren Duprey      | Member of Executive Committee |
| Marcello Agosti    | Member of Executive Committee |
| Milano Furuta      | Member of Executive Committee |
| Mwana Lugogo       | Member of Executive Committee |
| Ramona Sequeira    | Member of Executive Committee |
| Takako Ohyabu      | Member of Executive Committee |
| Teresa Bitetti     | Member of Executive Committee |
| Thomas Wozniewski  | Member of Executive Committee |
| Yoshihiro Nakagawa | Member of Executive Committee |
|                    |                               |